Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KNSA NASDAQ:MRSN NASDAQ:OMER NASDAQ:PRAX NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKNSAKiniksa Pharmaceuticals International$37.89+2.3%$35.48$17.82▼$39.43$2.74B0.16395,679 shs298,842 shsMRSNMersana Therapeutics$10.30+3.9%$7.55$5.21▼$70.75$49.46M0.962,960 shs47,556 shsOMEROmeros$4.10-2.1%$4.24$2.95▼$13.60$285.15M2.321.01 million shs731,975 shsPRAXPraxis Precision Medicines$52.52+0.3%$47.44$26.70▼$91.83$1.10B2.62426,307 shs136,244 shsSTOKStoke Therapeutics$34.94+15.2%$21.76$5.35▼$35.08$1.66B1.241.26 million shs1.90 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKNSAKiniksa Pharmaceuticals International+2.32%-0.60%+2.13%+33.32%+42.28%MRSNMersana Therapeutics+3.94%+29.40%+44.26%+21.43%-80.00%OMEROmeros-2.15%-7.66%-1.20%+16.81%+3.27%PRAXPraxis Precision Medicines+0.34%+0.92%+39.27%-2.07%-25.01%STOKStoke Therapeutics+15.16%+27.94%+48.93%+193.61%+173.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKNSAKiniksa Pharmaceuticals International$37.89+2.3%$35.48$17.82▼$39.43$2.74B0.16395,679 shs298,842 shsMRSNMersana Therapeutics$10.30+3.9%$7.55$5.21▼$70.75$49.46M0.962,960 shs47,556 shsOMEROmeros$4.10-2.1%$4.24$2.95▼$13.60$285.15M2.321.01 million shs731,975 shsPRAXPraxis Precision Medicines$52.52+0.3%$47.44$26.70▼$91.83$1.10B2.62426,307 shs136,244 shsSTOKStoke Therapeutics$34.94+15.2%$21.76$5.35▼$35.08$1.66B1.241.26 million shs1.90 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKNSAKiniksa Pharmaceuticals International+2.32%-0.60%+2.13%+33.32%+42.28%MRSNMersana Therapeutics+3.94%+29.40%+44.26%+21.43%-80.00%OMEROmeros-2.15%-7.66%-1.20%+16.81%+3.27%PRAXPraxis Precision Medicines+0.34%+0.92%+39.27%-2.07%-25.01%STOKStoke Therapeutics+15.16%+27.94%+48.93%+193.61%+173.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKNSAKiniksa Pharmaceuticals International 2.78Moderate Buy$45.4319.90% UpsideMRSNMersana Therapeutics 2.71Moderate Buy$56.60449.51% UpsideOMEROmeros 2.57Moderate Buy$18.00339.02% UpsidePRAXPraxis Precision Medicines 2.75Moderate Buy$85.5662.90% UpsideSTOKStoke Therapeutics 2.88Moderate Buy$30.83-11.75% DownsideCurrent Analyst Ratings BreakdownLatest MRSN, KNSA, STOK, OMER, and PRAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$38.00 ➝ $44.0010/13/2025STOKStoke TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $39.0010/10/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $35.0010/8/2025KNSAKiniksa Pharmaceuticals InternationalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025MRSNMersana TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025OMEROmerosWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PRAXPraxis Precision MedicinesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025STOKStoke TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/6/2025KNSAKiniksa Pharmaceuticals InternationalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/29/2025KNSAKiniksa Pharmaceuticals InternationalTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.009/27/2025KNSAKiniksa Pharmaceuticals InternationalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKNSAKiniksa Pharmaceuticals International$423.24M6.63N/AN/A$6.60 per share5.74MRSNMersana Therapeutics$40.50M1.27N/AN/A($1.92) per share-5.36OMEROmerosN/AN/AN/AN/A($3.15) per shareN/APRAXPraxis Precision Medicines$8.55M129.30N/AN/A$23.90 per share2.20STOKStoke Therapeutics$36.56M52.37N/AN/A$4.32 per share8.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKNSAKiniksa Pharmaceuticals International-$43.19M$0.04947.49151.56N/A0.90%1.05%0.80%11/4/2025 (Estimated)MRSNMersana Therapeutics-$69.19M-$14.62N/AN/AN/A-212.94%N/A-54.85%11/12/2025 (Estimated)OMEROmeros-$156.82M-$2.11N/AN/AN/AN/AN/A-55.49%11/12/2025 (Estimated)PRAXPraxis Precision Medicines-$182.82M-$12.29N/AN/AN/AN/A-60.07%-54.84%11/5/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.8541.11N/AN/A26.25%18.32%15.48%11/4/2025 (Estimated)Latest MRSN, KNSA, STOK, OMER, and PRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025MRSNMersana Therapeutics-$1.44N/AN/AN/A$14.20 millionN/A11/12/2025Q3 2025OMEROmeros-$0.58N/AN/AN/AN/AN/A11/5/2025Q3 2025PRAXPraxis Precision Medicines-$3.45N/AN/AN/A$0.06 millionN/A11/4/2025Q3 2025KNSAKiniksa Pharmaceuticals International$0.31N/AN/AN/AN/AN/A11/4/2025Q3 2025STOKStoke Therapeutics-$0.56N/AN/AN/AN/AN/A8/14/2025Q2 2025OMEROmeros-$0.55-$0.53+$0.02-$0.43$0.31 million$28.60 million8/13/2025Q2 2025MRSNMersana Therapeutics-$3.75-$4.08-$0.33-$4.87$6.06 million$3.06 million8/12/2025Q2 2025STOKStoke Therapeutics-$0.57-$0.40+$0.17-$0.40$31.51 million$13.82 million8/4/2025Q2 2025 & Study ResultPRAXPraxis Precision Medicines-$3.40-$3.31+$0.09-$3.31$0.15 millionN/A7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKNSAKiniksa Pharmaceuticals InternationalN/A3.573.16MRSNMersana TherapeuticsN/A1.351.35OMEROmerosN/A0.810.81PRAXPraxis Precision MedicinesN/A6.316.31STOKStoke TherapeuticsN/A6.986.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKNSAKiniksa Pharmaceuticals International53.95%MRSNMersana Therapeutics93.92%OMEROmeros48.79%PRAXPraxis Precision Medicines67.84%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipKNSAKiniksa Pharmaceuticals International53.48%MRSNMersana Therapeutics13.00%OMEROmeros12.90%PRAXPraxis Precision Medicines2.70%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKNSAKiniksa Pharmaceuticals International22074.11 million34.48 millionOptionableMRSNMersana Therapeutics1504.99 million4.34 millionOptionableOMEROmeros21068.06 million59.28 millionOptionablePRAXPraxis Precision Medicines11021.05 million20.48 millionOptionableSTOKStoke Therapeutics10054.80 million49.59 millionOptionableMRSN, KNSA, STOK, OMER, and PRAX HeadlinesRecent News About These CompaniesBTIG Maintains Stoke Therapeutics (STOK) Buy RecommendationOctober 14 at 3:37 PM | msn.comStoke Therapeutics (NASDAQ:STOK) Sets New 12-Month High Following Analyst UpgradeOctober 14 at 1:39 PM | marketbeat.comBTIG Research Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) StockOctober 14 at 8:16 AM | marketbeat.comStoke Therapeutics Earns Composite Rating UpgradeOctober 13 at 11:03 AM | msn.comStoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00October 13 at 2:27 AM | americanbankingnews.comEdward Md Kaye Sells 25,000 Shares of Stoke Therapeutics (NASDAQ:STOK) StockOctober 11, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Needham & Company LLCOctober 11, 2025 | marketbeat.comNeedham Maintains Stoke Therapeutics (STOK) Buy RecommendationOctober 10, 2025 | msn.comWhat 4 Analyst Ratings Have To Say About Stoke TherapeuticsOctober 10, 2025 | benzinga.comStoke Therapeutics price target raised to $35 from $22 at NeedhamOctober 10, 2025 | msn.comBiogen, Stoke Therapeutics present follow-up analyses from zorevunersen studiesOctober 10, 2025 | msn.comWhy Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet SyndromeOctober 10, 2025 | finance.yahoo.comWhat is Leerink Partnrs' Estimate for STOK FY2027 Earnings?October 10, 2025 | marketbeat.comBiogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying ...October 9, 2025 | markets.businessinsider.comStoke, Biogen presents new data from OLE studies of zorevunersenOctober 9, 2025 | msn.comStoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying ...October 9, 2025 | finance.yahoo.comStoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains?October 9, 2025 | zacks.comStoke Therapeutics (NASDAQ:STOK) Given "Sell (D+)" Rating at Weiss RatingsOctober 9, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading Volume - Here's WhyOctober 8, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) General Counsel Sells $250,700.00 in StockOctober 8, 2025 | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from AnalystsOctober 8, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 20252 AI Stocks With Record Breaking Rallies: Can They Continue?By Dan Schmidt | September 29, 2025New Catalysts Build Positive Pressure on Intel StockBy Jeffrey Neal Johnson | September 18, 2025AST SpaceMobile's Big Win: Shares Soar on New Deal With VerizonBy Leo Miller | October 11, 2025MRSN, KNSA, STOK, OMER, and PRAX Company DescriptionsKiniksa Pharmaceuticals International NASDAQ:KNSA$37.89 +0.86 (+2.32%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$38.82 +0.93 (+2.47%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Mersana Therapeutics NASDAQ:MRSN$10.30 +0.39 (+3.94%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$10.28 -0.03 (-0.24%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Omeros NASDAQ:OMER$4.10 -0.09 (-2.15%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$4.14 +0.04 (+1.10%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Praxis Precision Medicines NASDAQ:PRAX$52.52 +0.18 (+0.34%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$52.52 0.00 (0.00%) As of 10/14/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Stoke Therapeutics NASDAQ:STOK$34.94 +4.60 (+15.16%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$34.23 -0.71 (-2.03%) As of 07:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
